Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reach-Control: Toujeo vs Standard of Care in T2DM
NCT02967224Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2015
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Toujeo with Standard of Care (2 arms). Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c) at 6 months. Started Nov 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02967224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967224.